HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers

In Vitro

HB007 (compound 24) (0.1-100 μM) inhibits LN229 cell growth in a concentration-dependent manner t. HB007 (10-25 μM) reduces SUM01 conjugation and total protein levels of SUM01 but not SUM02/3 or UB in LN229 cells t. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HB007 (compound 24) (25-50 mg/kg; i.p. for 15 d) significantly suppresses tumor growth of colon and lung cancer but had no effect on the body weights of mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:SUMO1

Spezifikationen

Spezifikationen & Reinheit

≥99%

Biochemische und physiologische Mechanismen

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

INHIBITOR

Reinheit

≥99%

Namen und Kennungen

Molekulargewicht

328.78

Erweiterte Daten

Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)

C of A & Other Certificates(BSE/TSE, COO):

Analytical Chart:

Chemische und physikalische Eigenschaften

Löslichkeit	DMSO : 31.25 mg/mL (95.05 mM; ultrasonic and warming and heat to 60°C)

Lösungsrechner

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Reconstitution Calculator

Bewertungen

Application Protocols

No tested applications or protocols are specified for HB007 in the Product Data.

General screening workflow (guidance, not item-specific)

Stock preparation: Dissolve in anhydrous DMSO to 10–20 mM. Vortex/sonicate briefly if needed. Filter through 0.22 µm PTFE for particulate removal.
Plate handling: Aliquot into low-bind plates/tubes. Seal to minimize DMSO evaporation. Store at −20°C and avoid repeated freeze–thaw by using single-use aliquots.
Assay addition: Dilute into assay media to desired final concentration, maintaining solvent at ≤0.1–0.5% v/v. Mix gently and equilibrate per assay SOP.
Data integrity: Record lot number, purity, stock concentration, and dilution scheme on each plate map. Include vehicle controls and, where relevant, detergent or serum to mitigate aggregation or nonspecific binding.

Item-specific protocols and recommended dilutions: Not specified for this item; refer to CoA/Spec Sheet.

Biological Roles

Item-specific biological targets, pathways, or roles for HB007 are not provided in this listing.

General considerations for screening compounds

Potential roles are entirely structure- and context-dependent (e.g., enzyme modulation, receptor binding, pathway perturbation). Definitive roles must be established empirically in your assay system.
Annotate experimental conditions rigorously (compound lot, purity, concentration, DMSO %, exposure time) to ensure reproducibility and facilitate SAR if analogs are explored.
For cell-based assays, assess cytotoxicity/viability in parallel (e.g., resazurin, ATP-based assays) to discriminate specific responses from general stress or solvent effects.
Evaluate off-target and aggregation risks: include detergent controls or dynamic light scattering when working at higher micromolar concentrations with hydrophobic compounds.

Important

No medical or clinical claims are made for this product. It is supplied strictly for research use. Any biological activity must be determined by the end user under their specific experimental conditions.

Buffer Applications

This product is not a buffering reagent. No acid/base parameters (pKa) or buffering capacity are provided.

Practical note

For biochemical assays involving HB007, choose a buffer based on your biological target (e.g., HEPES pH 7.4 for many enzymes), then introduce HB007 from a concentrated DMSO stock to keep final DMSO ≤0.1–0.5% v/v as assay permits.
If solubility or stability appears pH-dependent, perform a small pH-solubility screen (e.g., pH 5.5, 7.4, 8.5) with constant cosolvent content and verify by LC–MS.

Item-specific buffer guidance: Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

Without item-specific solvent or process requirements, green considerations focus on solvent choice and sample handling during screening.

Greener choices (general guidance)

Prefer aqueous buffers with minimal cosolvent where assay allows. Keep DMSO at the lowest effective percentage (≤0.1–0.2% v/v when feasible).
If organic cosolvent is necessary, consider ethanol or isopropanol over DMF/NMP from an EHS perspective, balancing solubility and assay tolerance.
Use micro-scale assay formats and pre-aliquoted plates to reduce waste and repeated freeze–thaw.

Comparison (general)

DMSO vs 2-methyltetrahydrofuran (2-MeTHF): For stock preparation, DMSO remains standard due to water miscibility and assay compatibility; 2-MeTHF is greener but poorly miscible with water and rarely suitable for biological assays.
DMF/NMP vs ethanol: Ethanol offers a better environmental profile but lower solvency for very lipophilic molecules; validate solubility and assay performance.

Operational improvements

Implement plate sealing with low-permeation films to limit DMSO evaporation and emissions.
Consolidate shipments (as feasible) and use dry ice/ice packs efficiently to reduce cold-chain footprint without compromising product integrity.

All recommendations are general. For HB007-specific restrictions or greener substitutions, consult the CoA/Spec Sheet and your EHS team.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or manufacturing use is provided for HB007.

General guidance (research-only compound)

Intended use: research and screening. Not for human or veterinary use, drug substance, or excipient applications.
If considering HB007 for pre-formulation research (in vitro only), compile its physiochemical profile (solubility vs pH, logD, chemical stability) from the Spec Sheet and your internal studies. Avoid extrapolating to clinical contexts.
For any scale-up or GLP-adjacent work, request extended QC documentation (impurity profile, residual solvents, water content) and stability data; however, such specifications are not provided in this catalog entry and may require custom support.

Item-specific pharmaceutical information: Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific physicochemical data are not disclosed in this catalog entry.

Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Melting/Freezing Point: Not specified for this item; refer to CoA/Spec Sheet.
Boiling Point: Not specified for this item; refer to CoA/Spec Sheet.
Density: Not specified for this item; refer to CoA/Spec Sheet.
Refractive Index: Not specified for this item; refer to CoA/Spec Sheet.
LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
pKa: Not specified for this item; refer to CoA/Spec Sheet.
Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/practice, not item-specific)

Screening compounds are commonly shipped as dry powders or pre-dissolved DMSO aliquots. Typical working stocks: 10–50 mM in anhydrous DMSO; dilute into assay buffer immediately before use to minimize DMSO carryover (commonly ≤0.1–0.5% v/v final).
If the solid form is provided, evaluate solubility hierarchically: DMSO > DMF > ethanol/isopropanol > aqueous buffer with cosolvent/surfactant (e.g., 0.01–0.05% Tween-20 if assay-compatible).
For hygroscopic or low-melting materials, handle at ambient ≤20–22°C, cap promptly, and backfill with inert gas if specified on CoA.

Verification

For any quantitative property required for method development (e.g., extinction coefficient, pKa, partition ratio), consult the CoA/Spec Sheet or request analytical characterization from Aladdin Scientific.

Quality and Grades

Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret quality for screening compounds (general guidance)

Research grade screening compounds are typically qualified by identity (NMR/HRMS/LC–MS) and purity by HPLC/UPLC (area%) at a defined UV wavelength. The Spec Sheet/CoA will report assay purity, analytical conditions, and residual solvent levels where relevant.
If optical activity or stereochemistry is critical, the CoA may include chiral HPLC or enantiomeric excess. For tautomeric or salt forms, the precise form is indicated on labeling.
Lot-to-lot consistency: We perform incoming QC and release testing per internal SOPs. Request CoA for your lot to confirm identity, purity specification, and any stabilizers/additives.

Stabilizers and formulation

Stabilizer/antioxidant: Not specified for this item; refer to CoA/Spec Sheet. If present, stabilizers are chosen to preserve chemical integrity during storage/shipment and should be considered in biological assays.

Recommendations

For bioassay or analytical method development, verify purity on your platform (orthogonal HPLC or LC–MS). If low-UV impurities may interfere, request low-UV chromatographic conditions or use MS-based detection.
If you require elevated purity thresholds (e.g., ≥98% by qNMR), custom purification and documentation can be arranged on request.

Reaction and Applications

This product is supplied as a small-molecule screening compound intended for research use in discovery workflows. No item-specific reactivity or application claims are provided in the Product Data.

Typical uses for screening compounds (general, non-item-specific)

Primary screening and hit validation in biochemical or cell-based assays where the structure and purity are documented in the CoA/Spec Sheet.
Orthogonal assay confirmation, counter-screening, and mechanism-of-action hypothesis generation alongside reference controls.
Analytical method development: retention time indexing, MS method tuning, and stability-indicating method qualification under forced-degradation regimes (light, heat, oxidative, pH).

Practical guidance

Prepare concentrated DMSO stocks (e.g., 10–20 mM) and minimize DMSO in assay (<0.5% v/v) to reduce solvent effects.
If adsorption to plastics is suspected (lipophilic compounds), use low-bind PP or glass vials and include carrier protein (e.g., 0.1% BSA) only if assay-compatible.
For stability assessments, run time-course LC–MS at relevant temperatures and media; capture any hydrolysis/oxidation pathways to inform assay timing and storage.

Note

Because structure/functional groups are not disclosed here, we do not provide reaction chemistry (synthetic transformations) for this item. If you intend to use HB007 as a synthetic intermediate, request full structural and reactivity data via CoA before planning transformations.

Reaction Conditions

Item-specific reaction conditions are not applicable because HB007 is supplied as a screening compound with undisclosed structure in this entry.

General guidance (if using as a reagent or substrate after obtaining structure)

Solvent: Choose based on functional groups and solubility (e.g., polar aprotics for SNAr or coupling; alcohols for solvolysis or acylations when compatible).
Temperature: Start at ambient; adjust per reaction kinetics and stability studies. Confirm thermal stability by DSC/TGA or solution-phase stress testing.
Atmosphere: Use inert gas (N2/Ar) for air/moisture-sensitive motifs; add molecular sieves or dry bases as needed.
Catalysts/bases: Select per transformation (e.g., Pd cross-coupling with appropriate ligand/base system; carbodiimides or uronium salts for amide formation).

Because no structural data are provided here, these points are general and should not be taken as item-specific recommendations.

Safety and Handling

Safety information specific to HB007 is not provided in this listing and may be structure-dependent.

GHS Classification: Not specified for this item; refer to SDS.
Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (good practice)

PPE: Wear lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Use in a fume hood to avoid inhalation of dusts/vapors.
Avoid ingestion, inhalation, and skin/eye contact. Wash hands thoroughly after handling. Do not pipette by mouth.
Storage incompatibilities: Until specific functional groups are known, segregate away from strong oxidizers, strong acids/bases, and ignition sources. Keep container tightly closed under dry, inert atmosphere if noted on CoA.
First aid (overview; defer to SDS): Skin/eye contact—flush with water for ≥15 min; remove contaminated clothing. Inhalation—move to fresh air. Ingestion—rinse mouth, seek medical attention.
Spill response: Avoid dust generation. Absorb with inert material (e.g., vermiculite), collect in labeled waste. Decontaminate surface with suitable solvent consistent with your EHS guidelines.
Waste: Dispose of as organic chemical waste in accordance with institutional and local regulations.

Important

Always consult the product-specific SDS shipped with the item or request from Aladdin Scientific before first use. Hazards for screening compounds may vary widely depending on structure and impurities.

Solvent Selection

Item-specific solubility data are not disclosed. The following workflow reflects common practice for small-molecule screening compounds.

Preferred stock solvent

DMSO (anhydrous) is the default due to broad solvating power and assay compatibility at ≤0.1–0.5% v/v. Prepare 10–50 mM stocks, filter (0.22 µm PTFE) if needed, and aliquot to minimize freeze–thaw cycles.

Secondary options (when DMSO is unsuitable)

Polar aprotic: DMF, NMP (high solvency; validate cytotoxicity in cell assays).
Protic organics: Ethanol or isopropanol (good for moderately lipophilic compounds; evaporate before aqueous addition if needed).
Aqueous systems: PBS, HEPES, or assay buffer with 1–10% cosolvent (DMSO/EtOH) or minimal nonionic surfactant when compatible.

Decision criteria

Polarity and ionization: If the compound is basic/acidic (per CoA), aqueous solubility may improve by salt formation or pH adjustment (use buffers within assay tolerance).
Photolability/oxidation: If flagged on CoA, work under low light and add oxygen scavengers/inert atmosphere as appropriate.

Comparison (general)

DMSO: Broadest solubility, excellent stability; may interfere in some enzymatic assays at >0.5%.
DMF/NMP: Strong solvency; higher EHS burden—use only when necessary.
Ethanol/IPA: Lower toxicity profile; limited for highly lipophilic solids.

Always confirm solubility/compatibility empirically and consult the item’s Spec Sheet for any solvent restrictions.

Storage and Reconstitution

Item-specific storage from Product Data

Storage Conditions: Store at −20°C.
Shipped In: Ice chest + ice pads.

General best practices (complementary guidance)

Upon receipt: Inspect packaging temperature. Allow to equilibrate to room temperature in a desiccator before opening to prevent condensation.
Solid form: If supplied as a dry powder, promptly subdivide under dry conditions (glovebox or dry box if hygroscopic). Backfill with inert gas if specified on the CoA. Protect from light if photolabile.
Solution form: If supplied in DMSO, keep tightly sealed, minimize headspace, and store aliquots at −20°C. Avoid repeated freeze–thaw; use single-use aliquots.

Reconstitution (general, not item-specific)

Solvent: Prefer anhydrous DMSO for initial stock (typical 10–50 mM). If aqueous use is required, dilute the DMSO stock into buffer immediately before use to limit precipitation and degradation.
Filtration: If particulate is observed, filter through 0.22 µm PTFE (organic) or PVDF (aqueous) filters.
Stability: Monitor by LC–MS/HPLC after initial dissolution and periodically during storage to confirm integrity.

Important notes

Any item-specific cautions (e.g., moisture sensitivity, light sensitivity, recommended diluents) are Not specified for this item; refer to CoA/Spec Sheet.
For research use only, as stated in Product Data.

Structure and Identity

Concise identity summary for HB007 (screening compound entry).

SKU: H649579
Product Name: HB007
CAS: 2387821-46-5
Category: Small molecules and compound libraries (screening collection)
InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

Functional groups, ring systems, stereochemistry: Not specified for this item; refer to CoA/Spec Sheet.
2D description: Not available. When provided, we describe heteroatoms, aromaticity, substituent pattern, and stereocenters.

Notes for researchers

This listing is part of a curated screening set. Where structure-disclosing data are restricted, detailed identifiers (SMILES/InChI) and analytical data are supplied on request under CoA/NDA as applicable.
If you need computed identifiers (InChIKey, canonical SMILES), please reference the structure supplied with your shipment or request the Spec Sheet to ensure exact isomer/tautomer is captured.

Synthetic Utility

HB007 is listed as a screening compound. No structural information, functional groups, or reactivity data are provided; therefore, synthetic utility as a building block cannot be assessed from this entry.

General notes

If you intend to use HB007 as a synthetic intermediate, obtain the full structural disclosure (SMILES/InChI, functional groups, protecting groups, salt form) from the CoA/Spec Sheet first.
With confirmed structure, consider standard transformations aligned to its functional motifs (e.g., cross-coupling for aryl halides, amide formations for carboxylic acids/amines, nucleophilic substitutions for activated electrophiles). Without such details, proposing conditions would be speculative.

Recommendation

Request analytical package (1H/13C NMR, LC–MS, purity trace) and any stability notes prior to planning synthetic manipulations. Custom analog synthesis services may be available through Aladdin Scientific upon request.

Target Specificity

Target information for HB007 is not provided in the Product Data.

Verified targets, binding affinities, selectivity panels, or pathway annotations: Not specified for this item; refer to CoA/Spec Sheet or screening data supplied under separate agreement.

Note

For screening compounds, any target specificity must be established experimentally in your assay system. Include appropriate positive/negative controls and counterscreens to confirm on-target activity.

Häufig gestellte Fragen

What is the purity of this product?

This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2387821-46-5, the molecular formula is C15H9ClN4OS, and the molecular weight is 328.78 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Massen- & Individuellverpackung Benötigen Sie größere Mengen oder individuelle Spezifikationen? Kontaktieren Sie unser Team für ein maßgeschneidertes Angebot.

HB007 - ≥99% , CAS No.2387821-46-5

Übersicht